Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rebuild Study: Bydureon add-on to insulin versus insulin alone in type 2 diabetes after PCI
2015-000846-42Phase 3Active
- Sponsor
- Södersjukhuset
- Start
- May 2015
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial of exenatide in type 2 diabetes mellitus (T2DM) and coronary arteriosclerosis (2 arms), sponsored by Södersjukhuset. Primary endpoint: Primary endpoint: degree of non-covered stent struts at 3 months. Started May 2015; status: active.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)coronary arteriosclerosis
Beyond the preview
Go deeper on 2015-000846-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000846-42.